Boryung eying sales of 10 billion won with new drug

Published: 2011-09-19 06:58:00
Updated: 2011-09-19 06:58:00
Boryung Pharmaceutical Co. says its new drug for hypertension “Kanarb (fimasartan)”, angiotensin II receptor antagonist with a selective AT1 receptor blockade effect, is expected to achieve a 10 billion won in sales within one year since its launch in March.

Such robust sales will be possible ...

Fees

- Email service daily and homepage access.
  1. $300 per month. ($3,240 per year)
  2. 5 Email holders per each company.
  3. Anual contract base.



Most Read News


TOP
BACK
Address: 295-1, Chungpa-Ro, Yongsan-Gu, Korea
Phone: 02-3270-0114 | Fax: 02-3270-0129 | Email: eyd@yakup.com

Copyright © Yakup Shinmoon, Inc. All Rights Reserved.